Immix Biopharma Inc. Common Stock (IMMX)
Stock · NASDAQ · Health Care
$7.97as of 10/16/2026
Price chart
Active signals
IMMX Signal Track Record
How signals performed across all stocks →What IMMX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 42 | -4.5% | 40% | September 18, 2026 |
| Bollinger Band Breakout | 29 | -3.0% | 48% | August 11, 2026 |
| 200-Day Moving Average TouchActive now | 14 | -2.5% | 43% | October 8, 2026 |
| Bollinger Band Breakdown | 13 | +2.7% | 69% | October 2, 2026 |
| Any 20-session window (baseline) | +1.9% | 53% |
Computed by MarketWall from daily closing prices since October 3, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About IMMX
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 21
- Website
- immixbio.com/
Fundamentals
- 1-day range
- $8.47$8.91
- Market cap
- $702.09M
- P/E (trailing)
- —
- P/E (forward)
- -10.24
- EPS (trailing)
- $-0.87
- Dividend yield
- —
- Beta
- 0.22
- Avg. volume
- 1.65M
Forecasts
8 analyst ratings
Immix Biopharma Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- IMMXImmix Biopharma Inc. Common Stock$7.98▼ 8.06%Market cap $702.09MP/E —$2.31$15.1
- ZVRAZevra Therapeutics Inc. Common Stock$9.94▼ 3.21%Market cap $702.29MP/E 10.81$8.01$15.04
- IRWDIronwood Pharmaceuticals Inc. Class A Common Stock$3.5▼ 7.16%Market cap $701.25MP/E 4.68$1.41$5.78
- BBOTBridgeBio Oncology Therapeutics Inc. Common Stock$2.82▼ 4.41%Market cap $703.34MP/E —$3.79$14.87
- EVOEvotec SE American Depositary Shares$1.38▼ 2.82%Market cap $693.72MP/E —$2.41$7.3
- GYREGyre Therapeutics Inc. Common Stock$6.08▼ 5.00%Market cap $713.53MP/E —$5.44$9.42
- HELPCybin Inc. Common Stock$10.55▼ 4.52%Market cap $688.02MP/E —$5.3$20.88
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| IMMX Immix Biopharma Inc. Common Stock | $702.09M | — | $7.98 | ▼ 8.06% | $2.31$15.1 |
| ZVRA Zevra Therapeutics Inc. Common Stock | $702.29M | 10.81 | $9.94 | ▼ 3.21% | $8.01$15.04 |
| IRWD Ironwood Pharmaceuticals Inc. Class A Common Stock | $701.25M | 4.68 | $3.5 | ▼ 7.16% | $1.41$5.78 |
| BBOT BridgeBio Oncology Therapeutics Inc. Common Stock | $703.34M | — | $2.82 | ▼ 4.41% | $3.79$14.87 |
| EVO Evotec SE American Depositary Shares | $693.72M | — | $1.38 | ▼ 2.82% | $2.41$7.3 |
| GYRE Gyre Therapeutics Inc. Common Stock | $713.53M | — | $6.08 | ▼ 5.00% | $5.44$9.42 |
| HELP Cybin Inc. Common Stock | $688.02M | — | $10.55 | ▼ 4.52% | $5.3$20.88 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare ConferenceYahoo · 10/5/2026
- Immix Biopharma Reports 89% Complete Response in NXC-201 AL Amyloidosis StudyYahoo · 10/5/2026
- Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common StockYahoo · 9/30/2026
- BofA Raises Odds Of Success For Immix Biopharma’s NXC-201 Therapy — Sees Over 190% Upside In IMMX StockYahoo · 9/29/2026
- Needham Maintains Buy on Immix Biopharma, Raises Price Target to $30benzinga · 9/29/2026
- Immix Biopharma, Inc. (IMMX) Shareholder/Analyst Call TranscriptSeekingAlpha · 9/29/2026
- Immix Biopharma Reports 89% Complete Response Rate in Phase 2 NXC-201 TrialYahoo · 9/29/2026
- Needham Maintains Buy on Immix Biopharma, Raises Price Target to $30Benzinga · 9/29/2026
- Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common StockYahoo · 9/29/2026
Insider Activity
Insider Actions →- Magda Marquet · May 22, 2026 · Grant6.3K
- Adams Helen C. · May 22, 2026 · Grant12.5K
- Adams Helen C. · May 22, 2026 · Grant6.3K
- BUCHAN JANE · May 22, 2026 · Grant12.5K
- Ng Carey · May 22, 2026 · Grant12.5K
- Ng Carey · May 22, 2026 · Grant6.3K
- Morris Gabriel S · May 22, 2026 · Grant500.0K
- Rachman Ilya M · May 22, 2026 · Grant500.0K
- Yekaterina Chudnovsky · May 22, 2026 · Grant12.5K
- Yekaterina Chudnovsky · May 22, 2026 · Grant6.3K
- Hsu Jason · May 22, 2026 · Grant12.5K
- Hsu Jason · May 22, 2026 · Grant6.3K
- Magda Marquet · May 22, 2026 · Grant12.5K
- BUCHAN JANE · May 22, 2026 · Grant6.3K
- CHANG NANCY T · May 22, 2026 · Grant6.3K
Institutional Ownership
March 31, 2026
- Total shares held
- 26.92M
- Total value held
- $240.71M
- Institutional holders
- 74
- Unknown4.80M
- Unknown3.69M
- Unknown2.55M
- Unknown1.79M
- Unknown1.75M
- Unknown1.64M
- Unknown1.23M
- Unknown1.00M
- Unknown969.1K
- Unknown740.0K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
IMMX Holds Shareholder and Analyst Call
Immix Biopharma hosted a shareholder and analyst conference call, sharing recent company updates and answering questions. The discussion gave participants insight into the company's current activities and outlook. Such calls can influence how investors view the business and its progress.
IMMX Holds Shareholder and Analyst Call. Immix Biopharma hosted a shareholder and analyst conference call, sharing recent company updates and answering questions. The discussion gave participants insight into the company's current activities and outlook. Such calls can influence how investors view the business and its progress.